Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of oral minoxidil 1 mg in women with androgenetic alopecia
2023-503383-17-01Phase 3Authorised
- Sponsor
- Cantabria Labs
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of minoxidil in androgenetic alopecia (AGA) (3 arms), sponsored by Cantabria Labs. Primary endpoint: Change from baseline in target area hair count at Week 24. Planned start Oct 2024; status: authorised.
02
Drugs
minoxidil
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on 2023-503383-17-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503383-17-01.